Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11004028 | 0.79 | — | — | |
| SCHEMBL17178021 | 0.78 | PTGS2 (0.38) | PTGS2 | |
| SCHEMBL1666465 | 0.76 | GRM2 (0.43) | PTGS2 | |
| SCHEMBL19259245 | 0.73 | PTGS2 (0.32) | PTGS2 | |
| SCHEMBL19259180 | 0.73 | PTGS2 (0.32) | PTGS2 | |
| SCHEMBL14372530 | 0.72 | ATP1A1 (0.34) | — | |
| SCHEMBL17162607 | 0.72 | PTGS2 (0.31) | PTGS2 | |
| SCHEMBL17162603 | 0.72 | PTGS2 (0.31) | PTGS2 | |
| SCHEMBL17162606 | 0.72 | PTGS2 (0.31) | PTGS2 | |
| SCHEMBL24690843 | 0.71 | PTGS1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323997-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV Healthcare UK (No.5) Limited (GB) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323997-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | IL17A, BET1, CD4 | PTGS2 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.